Nuformix PLC NXP002 data to be presented at 2022 ERS Congress
05 July 2022 - 4:00PM
RNS Non-Regulatory
TIDMNFX
Nuformix PLC
05 July 2022
Reach
5 July 2022
Nuformix plc
("Nuformix" or the "Company" or the "Group")
NXP002 data to be presented at the 2022 European Respiratory
Society Congress
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, is pleased to announce that both of the abstracts
submitted for presentation at the European Respiratory Society
("ERS") International Congress 2022 in Barcelona on September 4-6,
on its lead asset NXP002, have been peer-reviewed and accepted for
presentation. NXP002 is a potential novel inhaled treatment for
Idiopathic Pulmonary Fibrosis ("IPF").
Commenting, Dr Julian Gilbert, Non-executive Director of
Nuformix, said: " We believe NXP002 offers tremendous potential as
a novel inhaled treatment for IPF and potentially other fibrosing
interstitial lung diseases ("ILDs") . The Company is progressing a
pre-clinical programme to demonstrate how its proprietary new form
of tranilast can down regulate fibrosis and inflammation following
inhalation, whilst avoiding severe side effects, which are key
issues in the treatment of IPF and other ILDs. We are therefore
delighted that the abstracts describing our initial work have been
accepted following peer review.
"The ERS is a leading international respiratory congress. It
provides us the opportunity to share these positive data with the
scientific and clinical communities and, very importantly, the
congress is attended by all the major respiratory-focused
pharmaceutical companies. Ultimately, we will be looking to license
NXP002 and the congress offers us an important opportunity to
present and introduce NXP002 to potential licensing partners."
Enquiries:
Nuformix plc
Dr Julian Gilbert, Non-executive Via IFC Advisory
Director
Maddy Kennedy, Non-executive Director
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate
Finance) +44 (0) 20 3650 3650
John Howes (Corporate Broking) +44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe +44 (0) 20 3934 6630
Zach Cohen nuformix@investor-focus.co.uk
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with
potential for significant value and early licensing
opportunities.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRARIMRTMTTMMMT
(END) Dow Jones Newswires
July 05, 2022 02:00 ET (06:00 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Jul 2023 to Jul 2024